Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will attend the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum brings together experts in nasal drug development, providing a platform for Silo to discuss its progress with SPC-15, a nose-to-brain delivery system designed for the treatment of post-traumatic stress disorder (PTSD).
CEO Eric Weisblum emphasized the importance of engaging with key opinion leaders in the nasal delivery space as the company advances SPC-15. The recent preclinical data for SPC-15 demonstrated that the formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent with long-term stability findings, indicating a robust product profile. These results are critical as Silo moves toward regulatory milestones and potential clinical trials.
The IPAC-RS forum is a key event for companies involved in inhalation and nasal drug products, offering a venue to share scientific data and discuss regulatory challenges. Silo's participation highlights its commitment to developing innovative delivery mechanisms that could improve therapeutic outcomes for CNS conditions. The company's pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo collaborates with leading academic institutions to advance its research.
The announcement follows Silo's broader strategy to diversify its portfolio, which also includes a cryptocurrency treasury component. This dual focus on biopharmaceutical innovation and digital assets positions the company uniquely in the investment landscape. As Silo continues to meet development milestones, its participation in industry forums like the IPAC-RS event is expected to raise its profile among potential partners and investors.
For more information about Silo Pharma and its programs, visit silopharma.com. The full press release is available at https://ibn.fm/Dy4qf. The latest news and updates on SILO are posted in the company's newsroom at https://ibn.fm/SILO.
